Solexa
Company

Last deal

$75M

Amount

Post-IPO Equity

Stage

20.09.2006

Date

3

all rounds

$222.9M

Total amount

date founded

Financing round

General

About Company
Solexa is a company that develops and commercializes genetic analysis technologies, primarily in the US and UK.

Industry

Sector :

Subsector :

founded date

01.01.1998

Number of employees

Company Type

For Profit

Last funding type

Post-IPO Equity

IPO status

Private

Description

The company's main focus is on developing and commercializing genetic analysis technologies. Their flagship product, the Solexa Genome Analysis System, utilizes their own sequencing technology to enable a wide range of DNA analysis applications. This includes whole genome resequencing, gene expression analysis, and small RNA analysis. The system is designed to provide accurate and efficient results, making it a valuable tool for researchers and scientists in the field of genetics. Solexa primarily operates in the United States and the United Kingdom.
Contacts
Similar Companies
748

Genome

Genome Corp. develops and commercializes DNA sequencing technology.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Genetics, Health Care

Location

Providence, RI, USA

total rounds

1

total raised

$250K
Depixus

Depixus

Depixus develops a technology that extracts genetic and epigenetic information from single molecules of DNA and RNA.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Genetics, Life Science

Location

Paris, France

total rounds

4

total raised

$31.01M
PINNI

PINNI

Provider of technologies and services in gene analysis and proteomics

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Information Technology, Genetics

Location

Russia
InKaryo Corp.

InKaryo Corp.

InKaryo Corp offers cytogenetic analysis services.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Genetics, Health Care

Location

Santa Clara, CA, USA
M&A Details
1

Transaction name

Acquired by

Illumina

announced date

13.11.2006

price

$600M

Financials

Funding Rounds
7
3

Number of Funding Rounds

$222.9M

Money Raised

Their latest funding was raised on 20.09.2006. Their latest investor SV Health Investors. Their latest round Post-IPO Equity

Date 
Funding Round 
Investors 
Money Raised 
Lead 
21.11.2005
$65M
12.07.2005
$24M

Azimuth Opportunity

Azimuth Opportunity is a biotech-focused private equity firm.

Sector

Investment Banking and Brokerage Services

Subsector

Asset Managers and Custodians

Keywords

Biotechnology, Venture Capital, Financial Services

Location

New York, NY, USA

count Of Investments

3

count Of Exists

2
Co-Investors
Investors
7
3

Number of lead investors

7

Number of investors

Investor 
Lead 
Round 
Partners 
No
Venture - Series Unknown
Yes
Series A, Series B
No
Series B
SV Health Investors

SV Health Investors

SV Health Investors is a leading healthcare and life sciences venture capital and growth equity firm.

Sector

Closed End Investments

Subsector

Closed End Investments

Location

Boston, MA, USA

count Of Investments

260

count Of Exists

70
Schroder Ventures

Schroder Ventures

Schroders is a global investment manager serving institutions, intermediaries, and individuals globally.

Sector

Investment Banking and Brokerage Services

Subsector

Asset Managers and Custodians

Location

London, UK

count Of Investments

31

count Of Exists

19
Abingworth

Abingworth

Abingworth collaborates with entrepreneurs to develop impactful health products in life sciences.

Sector

Investment Banking and Brokerage Services

Subsector

Asset Managers and Custodians

Keywords

Financial Services, Venture Capital

Location

London, UK

count Of Investments

131

count Of Exists

45

People

Employee Profiles
7
Clive G. Brown

Clive G. Brown

Director of Computational Biology & IT

Shankar Balasubramian

Shankar Balasubramian

Founder

Garrison Morfit

Garrison Morfit

Former Director

Dian Georgia

Controller

David Klenerman

David Klenerman

Founder

Activity

Recent News
0